Ratings by Goldman Sachs (Corinne Johnson)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/2/2026 | Neurocrine Bio. | NBIX | New Coverage | Buy (N/A) |
161.00 (155.64) |
-3.33% | Details | |
| 5/15/2026 | ORIC Pharmaceuticals | ORIC | Upgrade | Buy (Early-Stage Biotech) |
8.34 (12.86) |
54.2% | Details | |
| 5/15/2026 | Prelude Therapeutics | PRLD | New Coverage | Early-Stage Biotech (N/A) |
4.47 (5.46) |
22.15% | Details | |
| 4/24/2026 | Altimmune | ALT | Upgrade | Neutral (Sell) |
2.89 (3.42) |
18.34% | Details | |
| 4/15/2026 | Immunovant | IMVT | Maintain | Neutral (N/A) |
|
Details | ||
| 4/1/2026 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2026 | Biohaven Pharma | BHVN | New Coverage | Buy (N/A) |
10.99 (15.69) |
42.77% | Details | |
| 12/4/2025 | Tyra Biosciences | TYRA | New Coverage | Early-Stage Biotech (N/A) |
21.70 (28.65) |
32.03% | Details | |
| 12/4/2025 | MBX Biosciences Inc | MBX | New Coverage | Sell (N/A) |
33.94 (61.72) |
81.85% | Details | |
| 12/4/2025 | ORIC Pharmaceuticals | ORIC | New Coverage | Early-Stage Biotech (N/A) |
10.98 (8.34) |
-24.04% | Details | |
| 11/4/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2025 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 8/27/2025 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 7/10/2025 | Nurix | NRIX | New Coverage | Buy (N/A) |
13.18 (26.14) |
98.33% | Details | |
| 7/10/2025 | Immunovant | IMVT | New Coverage | Neutral (N/A) |
17.29 (39.25) |
127.01% | Details | |
| 7/10/2025 | CG Oncology | CGON | New Coverage | Buy (N/A) |
27.04 (74.67) |
176.15% | Details | |
| 7/10/2025 | ArriVent BioPharma | AVBP | New Coverage | Buy (N/A) |
21.34 (30.95) |
45.03% | Details | |
| 7/10/2025 | Avidity Biosciences | RNA | New Coverage | Buy (N/A) |
31.27 (14.19) |
-54.62% | Details | |
| 7/10/2025 | Neurocrine Bio. | NBIX | New Coverage | Buy (N/A) |
128.74 (161.00) |
25.06% | Details | |
| 7/10/2025 | Syndax Pharmaceuticals | SNDX | New Coverage | Buy (N/A) |
8.75 (20.56) |
134.97% | Details | |
| 7/10/2025 | Geron Corporation | GERN | New Coverage | Sell (N/A) |
1.39 (1.57) |
12.95% | Details | |
| 7/10/2025 | Amylyx Pharmaceuticals inc. | AMLX | New Coverage | Buy (N/A) |
6.98 (34.10) |
388.54% | Details | |
| 7/10/2025 | Altimmune | ALT | New Coverage | Sell (N/A) |
4.58 (2.89) |
-36.9% | Details | |
| 10/30/2024 | Avidity Biosciences | RNA | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2024 | CG Oncology | CGON | Maintain | Buy (N/A) |
|
Details | ||
| 10/3/2024 | Avidity Biosciences | RNA | Maintain | Buy (N/A) |
|
Details | ||
| 9/26/2024 | CG Oncology | CGON | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2024 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 9/24/2024 | Avidity Biosciences | RNA | New Coverage | Buy (N/A) |
44.48 (14.19) |
-68.1% | Details | |
| 9/16/2024 | CG Oncology | CGON | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2024 | ArriVent BioPharma | AVBP | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2024 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 5/29/2024 | Immunovant | IMVT | Maintain | Neutral (N/A) |
|
Details | ||
| 5/14/2024 | CG Oncology | CGON | Upgrade | Buy (Neutral) |
28.50 (74.67) |
162% | Details | |
| 3/13/2024 | Immunovant | IMVT | New Coverage | Buy (N/A) |
31.50 (39.25) |
24.6% | Details | |
| 2/20/2024 | CG Oncology | CGON | New Coverage | Neutral (N/A) |
47.46 (28.50) |
-39.95% | Details | |
| 2/20/2024 | ArriVent BioPharma | AVBP | New Coverage | Buy (N/A) |
22.07 (30.95) |
40.24% | Details |
